ARCH:TSXV
ACHFF:OTC
Home
About us
Our story, our approach
Our Science
Pipeline, research & publications
Our Key Platforms
MetaBlok™
Treating, organ injury caused by inflammation
AB569
Treatment for Respiratory Pseudomonas aeruginosa Infections
BORG
Peptide Solid Surface Interface
MetaMx™
Brain Tumor Initiating Cell Targeting
Our Publications
Peer-reviewed scientific publications
AB569
Brain Tumor Stem Cell Targeting
BORG Peptide Solid Surface Interface
Treatments for Inflammation
Our Team
Management & lead scientists
Our Management
Governance, Executive, Board of Directors and Advisors
Our Principal Scientists
Learn about the scientists behind our technologies
MetaBlok™ and MetaMx™
AB569 & Respiratory Pseudomonas
BORG Peptide
Treatments for Inflammation
Investor Hub
Investor relations, fundamentals
Fundamentals
Press Releases
Investor Information
Stock Performance
Reports and Filings
Management Discussion and Analysis
Annual and Quarterly Reports
Proxies and Information Circulars
Material Change Documents
Other SEDAR Filings
Contact Us
Subcategories
Brain Tumor Stem Cell Targeting
Borg Peptide Solid Surface Interface
Treatments for Inflammation
AB569
Recent News
July 14th 2020
Arch Biopartners Engages Global CRO to Conduct LSALT peptide (Metablok) Phase II trial for Treatment of Complications in COVID-19 Patients in the U.S.
Read More
June 30th 2020
Arch Biopartners Closes Non-Brokered Private Placement
Read More
See All
Subscribe to News
Reports and Filings
Home
About us
Our Science
--Our Key Platforms
---MetaBlok™
---AB569
---BORG
---MetaMx™
--Our Publications
---AB569
---Brain Tumor Stem Cell Targeting
---BORG Peptide Solid Surface Interface
---Treatments for Inflammation
Our Team
--Our Management
--Our Principal Scientists
---MetaBlok™ and MetaMx™
---AB569 & Respiratory Pseudomonas
---BORG Peptide
---Treatments for Inflammation
Investor Hub
--Fundamentals
---Press Releases
---Investor Information
---Stock Performance
--Reports and Filings
---Management Discussion and Analysis
---Annual and Quarterly Reports
---Proxies and Information Circulars
---Material Change Documents
---Other SEDAR Filings
Contact Us
Home
About us
Our Science
Our Key Platforms
MetaBlok™
AB569
BORG
MetaMx™
Our Publications
AB569
Brain Tumor Stem Cell Targeting
BORG Peptide Solid Surface Interface
Treatments for Inflammation
Our Team
Our Management
Our Principal Scientists
MetaBlok™ and MetaMx™
AB569 & Respiratory Pseudomonas
BORG Peptide
Treatments for Inflammation
Investor Hub
Fundamentals
Press Releases
Investor Information
Stock Performance
Reports and Filings
Management Discussion and Analysis
Annual and Quarterly Reports
Proxies and Information Circulars
Material Change Documents
Other SEDAR Filings
Contact Us